Loading...

URGN UROGEN PHARMA LTD Management Changes 8-K Filing

RGN

RGN

UROGEN PHARMA LTD

(URGN)

2025 8-K

Patent Settlement

Financial Results Announcement

Financial Results Report

Loan Agreement Details

Financial Results Report

Shareholder Approvals

Financial Statements

Compensatory Arrangements o...

New Product Launches

Financial Statements

Financial Results

Asset Acquisition

Investor Presentation

Financial Results

Director Resignation

Financial Results

Annual Meeting Approval

Public Offering

Positive Data from Phase 3 ...

Financial Results Announcement

Financial Results Announcement

Presentation at Conference

Notice of ANDA Submission

Agreement and Phase 3 Study

Amendment to Manufacturing ...

Financial Results Announcement

Annual Meeting of Shareholders

Financial Results Announcement

Private Placement

Financial Results Announcement

External Links:

On June 30, 2025, UroGen Pharma Ltd. awarded special bonuses totaling $845,000 to three executives in recognition of their leadership prior to the FDA's approval of ZUSDURI for treating bladder cancer.

AI Assistant

UROGEN PHARMA LTD

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.